Merck & Co. - MRK Earnings per share for the last 12 months

Public company logo of Merck Sharp & Dohme (MRK)

The prospects for Merck & Co., Inc. (MRK) depend on new developments in cardiology and oncology due to the upcoming patent expiration of Keytruda. The current EPS YoY TTM growth rate confirms the resilience of this trend, with the value stabilizing at -87.20. Gardasil vaccine sales and dividend payments provide stability. The monopoly status of the flagship drug guarantees premium pricing power despite regulatory pressure in the US.

MRK Merck & Co.: Earnings per share for the last twelve months in the range 02/11/2024 - 11/14/2026

MRK (merck.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Price Chart Merck|MRK - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Merck Sharp & Dohme|MRK - Enterprise Value
- book capitalization indicators:
Net Assets per Share Merck|MRK - Company Book Value|Capitalization to Book Value Ratio merck.com|MRK - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Merck & Co., Inc.|MRK - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Merck & Co., Inc.|MRK - Company Aggregate Debts|Debts to Book Value MSD|MRK - Company Long-Term Debt|Company Short-Term Loans and Borrowings Merck|Quick Liquidity Indicator merck.com
- business earnings and investment ratios data:
MRK - Company Net Income|Projected Future Earnings Merck & Co., Inc.|MRK - Price to Earnings Ratio|Future Price to Earnings Multiple merck.com|MRK - Growth-Adjusted P/E Ratio|Enterprise Value to Operating Income Before Depreciation Ratio Merck|MRK - Operating profit before deduction of amortization|Earnings per share for the trailing year Merck|MRK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months merck.com|MRK - Earnings per share growth in current year|Expected net earnings per share growth next year Merck & Co., Inc.
- revenue and sales details:
MRK - Company Sales|Company Future Sales Merck Sharp & Dohme|MRK - Market Cap to Revenue|Forward Price to Sales Merck Sharp & Dohme
Fundamental company valuation:MRK, Merck & Co.
Signature product of Merck & Co., Inc.

Amidst a fierce battle for oncology leadership and the risks of patent expiration, Merck & Co., Inc. (MRK) is compelled to constantly scale its profits. This metric measures the percentage change in net earnings per share over a rolling year, reflecting the efficiency of R&D expenditures. This allows investors to distinguish organic growth from temporary market fluctuations. By analyzing the annual EPS growth rate over the last 12 months, one can assess the sustainability of the company's capitalization.

Competitor analysis

LLY: Earnings per share for the last twelve months|Abbvie (ABBV) - Earnings per share for the last twelve months|Earnings per share for the last 12 months AZN|NVS (novartis.com) - Net earnings per share (EPS TTM)|novonordisk.com (NVO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) AMGN|Pfizer - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SNY (Sanofi SA)|Net earnings per share for the trailing year BMS|gsk.com - Net earnings per share (EPS TTM)|Takeda Pharmaceutical - Earnings per share for the last four quarters|TEVA (tevapharm.com) - Net earnings per share for the last 12 months|Dr. Reddy's Lab - Earnings per share for the trailing year|VTRS (Mylan) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Roivant Sciences Ltd ROIV|Net earnings per share (EPS TTM) ZLAB|Net earnings per share for the last four quarters Bausch Health Companies|Earnings per share for the last twelve months Cosmos Health, Inc. COSM